产品说明书

Cisatracurium besylate

Print
Chemical Structure| 96946-42-8 同义名 : 顺苯磺酸阿曲库铵 ;51W89 besylate;Cisatracurium besilate;Cisatracurium (besylate);51W89
CAS号 : 96946-42-8
货号 : A153975
分子式 : C65H82N2O18S2
纯度 : 98%
分子量 : 1243.479
MDL号 : MFCD00871018
存储条件：

粉末 Sealed in dry,Store in freezer, under -20°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

H2O: 50 mg/mL(40.21 mM)
动物实验配方：
生物活性
靶点

  • Adrenergic Receptor
描述 Cisatracurium Besylate is an ideal non-depolarizing muscle relaxant. The inhibitory effect of cisatracurium besylate on the proliferation activity of endothelial cells was time-dependent. Cisatracurium Besylate (0, 5, 25, or 100 µM) make the number of the autolysomes increases in a concentration dependent manner. Moreover, cisatracurium besylate can injure cells through autophagic cell death[3]. Cisatracurium besylate is frequently used in the intensive care unit in order to induce muscle relaxation to facilitate mechanical ventilation in critically ill patients[4].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT01181349 - Completed - -
NCT02793323 Relieve Shoulder Pain After La... 展开 >>paroscopic Surgeries 收起 << Not Applicable Completed - Lebanon ... 展开 >> Makassed General Hospital Beirut, Lebanon 收起 <<
NCT02154074 Perioperative Blood Glucose an... 展开 >>d Insulin 收起 << Phase 4 Unknown October 2014 China, Shanxi ... 展开 >> SecondXianJiaotongU Recruiting Xi'an, Shanxi, China Contact: Hongtao Liu    13572225310    lannylouis@163.com 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

0.80mL

0.16mL

0.08mL

4.02mL

0.80mL

0.40mL

8.04mL

1.61mL

0.80mL
参考文献

[1]Zhang H, Wang P, et al. HPLC determination of cisatracurium besylate and propofol mixtures with LC-MS identification of degradation products. J Pharm Biomed Anal. 1998 Mar;16(7):1241-9.

[2]Dear GJ, Harrelson JC, et al. Identification of urinary and biliary conjugated metabolites of the neuromuscular blocker 51W89 by liquid chromatography/mass spectrometry. Rapid Commun Mass Spectrom. 1995;9(14):1457-64.

[3]Zhuang H, Tian W, Li W, Zhang X, Wang J, Yang Y, Liu X, Xia Z, Feng D, Zhang L. Autophagic Cell Death and Apoptosis Jointly Mediate Cisatracurium Besylate-Induced Cell Injury. Int J Mol Sci. 2016 Apr 6;17(4):515.

[4]Meeder AM, van der Steen MS, Rozendaal A, van Zanten AR. Phlebitis as a consequence of peripheral intravenous administration of cisatracurium besylate in critically ill patients. BMJ Case Rep. 2016 Oct 3;2016:bcr2016216448.